Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
NCT ID: NCT06006117
Last Updated: 2025-12-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
260 participants
INTERVENTIONAL
2023-09-05
2032-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The patients will be Randomized as follows:
Arm A - Experimental arm:
• Mosunetuzumab-Lenalidomide
Arm B - Comparator arms ( Investigator Choices):
* Rituximab-Lenalidomide
* Rituximab-Bendamustine
* Rituximab-CHOP
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients are stratified according to MZL subtypes and time to progression of disease after first-line within 2 years (POD24) \< 2 years or \> 2 years.
Mosunetuzumab will be administered sub-cutaneously (SC) (21 days first cycle, then 28 days next cycles) and Lenalidomide will be given PO 20 mg/day from Day 1 to Day 21 from cycles C2 to C6. For each patient, investigator choice had to be decided before randomization between Rituximab-Lenalidomide and Rituximab-chemotherapy (R-Bendamustine or R-CHOP).
The primary efficacy endpoint for comparison is the Progression-free survival (PFS) as determined by investigator (Lugano criteria 2014). Secondary objectives include CR24 as determined by investigator (at 24 months) according to Lugano criteria 2014 and by central review based on PET result, Overall response rate (ORR) and CR other than CR24 as determined by investigator, or by central review based on PET result according to Lugano Criteria 2014. 260 patients are planned to be enrolled in France, Belgium, Germany, Italy and Portugal
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
Arm B - Comparator arms (Investigator Choices):
* Rituximab-Lenalidomide
* Rituximab-Bendamustine
* Rituximab-CHOP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1: Mosunetuzumab and Lenalidomide
* Mosunetuzumab will be administered SC (21 days first cycle, then 28 days next cycles)
* C1 (21-days cycle): step-up dosing schedule 5 mg Day 1, 45 mg on Day 8 and 45 mg Day 15
* C2 to C12: 45 mg D1 28-days cycles
* Lenalidomide PO starting dose is based on patient's creatinine clearance from Day 1 to Day 21 from cycles C2 to C6 (cycles of 28 days)
Mosunetuzumab (SC)
○ Mosunetuzumab will be administered SC (21 days first cycle, then 28 days next cycles)
* C1 (21-days cycle): step-up dosing schedule 5 mg Day 1, 45 mg on Day 8 and 45 mg Day 15
* C2 to C12: 45 mg D1 28-days cycles
Lenalidomide
Cycles 2 to 6 (28-day cycles): starting dose is based on patient's creatinine clearance, from day 1 to day 21, once a day, rest period from day 22 to day 28
Arm 2: Rituximab-Lenalidomide (28-days cycles)
* Rituximab\* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2-12
* Lenalidomide PO starting dose is based on patient's creatinine clearance, D1-21 from cycle 1 to cycle 6
Rituximab (R)
Rituximab\* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2-12
Lenalidomide
Cycles 2 to 6 (28-day cycles): starting dose is based on patient's creatinine clearance, from day 1 to day 21, once a day, rest period from day 22 to day 28
Arm 3: Rituximab-Bendamustine (28-days cycles)
* Rituximab\* 375 mg/m2 intravenously at cycle 1 Day 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2 to 6\*\* (28-days cycles) and then at D1 of three additional 56-days cycles (C7 to C9). \*\*For patients in complete response (CR) at 3 cycles, if Bendamustine is stopped, then Rituximab should also be omitted for C5 and C6.
* Bendamustine IV 70 or 90 mg/m² (according to the investigator's judgment) D1 and D2/28 days x 6 cycles 28 days cycles). For patients in complete response (CR) at 3 cycles, Bendamustine and Rituximab could be stopped after 4 cycles at investigator discretion
Rituximab (R)
Rituximab\* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2-12
Bendamustine
○ Bendamustine IV 70 or 90 mg/m² (according to the investigator's judgment) D1 and D2/28 days x 6 cycles 28 days cycles). For patients in complete response (CR) at 3 cycles, Bendamustine and Rituximab could be stopped after 4 cycles at investigator discretion
Arm 4: Rituximab-CHOP (21-days cycles)
* Rituximab\* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2 to 6 (21-days cycles), and then at D1 of three additional 56-days cycles (C7 to C9)
* CHOP, IV standard dose from cycle 1 to 6
Rituximab (R)
Rituximab\* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2-12
CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)
CHOP, IV standard dose from cycle 1 to 6
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mosunetuzumab (SC)
○ Mosunetuzumab will be administered SC (21 days first cycle, then 28 days next cycles)
* C1 (21-days cycle): step-up dosing schedule 5 mg Day 1, 45 mg on Day 8 and 45 mg Day 15
* C2 to C12: 45 mg D1 28-days cycles
Rituximab (R)
Rituximab\* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2-12
Bendamustine
○ Bendamustine IV 70 or 90 mg/m² (according to the investigator's judgment) D1 and D2/28 days x 6 cycles 28 days cycles). For patients in complete response (CR) at 3 cycles, Bendamustine and Rituximab could be stopped after 4 cycles at investigator discretion
CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)
CHOP, IV standard dose from cycle 1 to 6
Lenalidomide
Cycles 2 to 6 (28-day cycles): starting dose is based on patient's creatinine clearance, from day 1 to day 21, once a day, rest period from day 22 to day 28
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Have been treated with at least one prior systemic treatment and not more than three prior lines. Previous line must include at least one systemic line with a drug targeting CD20 (monoclonal antibody at least 2 cycles; patient treated with monoclonal antibody monotherapy should have received at least 4 weekly injections) with or without chemotherapy (R-CHOP, R-Bendamustine, R-CVP, R-Chlorambucil at least 2 cycles) or targeted treatment such as Ibrutinib (at least 1 month). Patients previously treated by lenalidomide are eligible if the last administration of lenalidomide is superior to 12 months before C1D1. When randomized in comparator arm, those patients should require R-chemo. Prior local therapy (including surgery, radiotherapy antibiotics for H. pylori-positive gastric lymphoma, and antiviral for hepatitis C virus) is not considered as one line of treatment
3. Signed Informed Consent Form
4. Age ≥ 18 years at the time of signing the informed consent form
5. Ability to comply with the study protocol and procedures and required hospitalizations, in the investigator's judgement
6. Eastern Cooperative Oncology Group (ECOG) performance score (PS) of ≤ 2
7. Have a symptomatic disease requiring a systemic treatment
8. Not eligible for a local treatment including radiotherapy or surgery
9. Stage I disease of EMZL, SMZL or NMZL may be eligible only if not candidate to local therapy (surgery or radiotherapy).
10. Measurable disease in at least two perpendicular dimensions on an imaging scan is defined as: lymph node or nodal mass bi-dimensional measurement with ≥ 15 mm in longest transverse diameter or the short diameter must measure ≥ 10 mm regardless of the longest transverse diameter.
Spleen is considered as a measurable disease if vertical axis is higher than 13 cm.
11. Adequate hematopoietic function at screening as follows unless cytopenia is clearly due to marrow involvement of MZL or hypersplenism or autoimmune thrombocytopenia:
11.1. Platelet count ≥ 75 G/L; in cases of thrombocytopenia clearly due to marrow involvement of MZL or hypersplenism or auto-immune thrombocytopenia, platelet count should be ≥ 30 G/L Washout platelet transfusion is 7 days between transfusion and D1 of starting treatment
11.2. ANC ≥ 1 G/L unless neutropenia is clearly due to marrow involvement of MZL or hypersplenism. G-CSF is not allowed within 7 days before starting treatment
11.3. Total hemoglobin ≥ 8 g/dL unless anemia is clearly due to marrow involvement of MZL or hypersplenism or autoimmune hemolytic anemia. Washout erythrocyte transfusion is 7 days between transfusion and D1 of starting treatment
12. Serum total bilirubin ≤ 1.5 x the upper limit of normal (ULN) (or ≤3 x ULN for patients with Gilbert syndrome),
13. AST or ALT ≤ 2.5 x ULN, unless directly attributable to the patient's MZL
14. Measured or estimated creatinine clearance ≥ 40 mL/min by institutional standard method
15. Patients who are hepatitis B surface antigen (HBsAg) negative and hepatitis B core antibody (HBcAb) positive, must be negative for hepatitis B virus (HBV) polymerase chain reaction (PCR) to be eligible for study participation. Patients who are hepatitis B surface antigen (HBsAg) negative, hepatitis B surface antibody (anti-HBsAb) positive and hepatitis B core antibody (HBcAb) negative are eligible,
16. Contraception:
16.1. For women of childbearing potential (WOCBP): Serum test pregnancy at screening and Day 1 before first dose. And then monthly until end of chemotherapy or end of lenalidomide. Efficient contraceptive method is required during the treatment period (including periods of treatment interruption), for at least 28 days after the final dose of lenalidomide (if applicable), 3 months after the final dose of mosunetuzumab and tocilizumab (if applicable), 12 months after the final dose of CHOP (if applicable), 6 months after the final dose of bendamustine (if applicable) and 12 months after the final dose of rituximab (if applicable).
16.2. For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined below: With a female partner of childbearing potential or pregnant female partner, men must remain abstinent or use a condom during the treatment period (including periods of treatment interruption), and for at least 28 days after the final dose of lenalidomide (if applicable), 2 months after the final dose of tocilizumab (if applicable), 6 months after the final dose of CHOP (if applicable), 3 months after the final dose of bendamustine and 12 months after the final dose of rituximab (if applicable).
17. Patient covered by any social security system (France).
18. Patient who understands and speak one of the country official languages.
Exclusion Criteria
2. Participants who have received any of the following treatments prior to study entry:
* Treatment with mosunetuzumab or other CD20/CD3-directed bispecific antibodies
* Allogeneic stem cell transplant
3. Participants who have received any of the following treatments, whether investigational or approved, within the respective time periods prior to initiation of study treatment:
* Radiotherapy within 2 weeks prior to the first dose of study treatment
* Autologous stem cell transplant within 100 days prior to first study treatment
* Use of monoclonal antibodies within 4 weeks prior to first study treatment
* Systemic immunosuppressive medications (including, but not limited to, Cyclophosphamide, Azathioprine, Methotrexate, Thalidomide, and anti-tumor necrosis factor agents) within 2 weeks prior to first dose of study treatment (C1D1); Systemic corticosteroid treatment \<20 mg/day Prednisone or equivalent and inhaled corticosteroids are permitted. Last dose of corticosteroid ≥20 mg/day Prednisone or equivalent will not be permitted during the last 15 days before inclusion.
Administration of acute, low-dose, systemic immunosuppressant medications (e.g., single dose of 4 mg/day of dexamethasone for nausea or B-symptoms) is permitted during 4 days without washout.
\- Any other anti-cancer investigational therapy within 4 weeks prior to initiation of study treatment.
4. Pregnant or breastfeeding or intending to become pregnant during the study or within 28 days after the final dose of lenalidomide, 3 months after the final dose of mosunetuzumab and tocilizumab (if applicable), 12 months after the final dose of CHOP, 6 months after the final dose of bendamustine and 12 months after the final dose of rituximab (if applicable). Women of childbearing potential must have a negative serum pregnancy test result within 7 days prior to initiation of study treatment.
5. Received a live, attenuated vaccine within 4 weeks before first dose of study treatment, or in whom it is anticipated that such a live attenuated vaccine will be required during the study period or within 5 months after the final dose of study treatment, except for acute pandemic situation such COVID19
6. Active or history of CNS lymphoma or leptomeningeal infiltration
7. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibody therapy (or recombinant antibody-related fusion proteins) - grade 3 and 4
8. Known hypersensitivity to biopharmaceuticals produced in CHO cells or any component of the mosunetuzumab, rituximab, tocilizumab, lenalidomide, or thalidomide formulation, including Mannitol
9. Patients unable to receive adequate prophylaxis and/or therapy for thromboembolic events (aspirin or low molecular weight heparin)
10. History of prior malignancy, except for conditions as listed below if patients have recovered from the acute side effects incurred as a result of previous therapy:
* Malignancies treated with curative intent and with no known active disease present for ≥ 2 years before enrollment
* Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
* Adequately treated cervical carcinoma in situ without evidence of disease
* Surgically/adequately treated low grade, early stage I, localized prostate in situ carcinoma
11. Participants with infections requiring IV treatment with antibiotics or hospitalization (Grade 3 or 4) within the last 4 weeks prior to inclusion or known active bacterial, viral (including SARS-CoV-2), fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds),
12. Evidence of any significant, concomitant disease that could affect compliance with the protocol or interpretation of results, including, but not limited to:
* Significant cardiovascular disease \[e.g., Objective Class C or D heart diseases (cf. Classes of Heart Failure \| American Heart Association)\], myocardial infarction within the previous 6 months, unstable arrhythmia, or unstable angina)
* Significant pulmonary disease (such as obstructive pulmonary disease or history of bronchospasm)
* Clinically significant history of liver disease, including viral or other hepatitis, or cirrhosis
* Current or past history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease. Participants with a history of stroke who have not experienced a stroke or transient ischemic attack in the past 1 year and have no residual neurologic deficits as judged by the investigator are allowed. Participants with a history of epilepsy who have had no seizures in the past 2 years with or without anti-epileptic medications can be eligible.
13. History of confirmed progressive multifocal leukoencephalopathy (PML)
14. Known Positive serologic HIV test at screening
15. Acute or chronic hepatitis C virus (HCV) infection Participants who are positive for HCV antibody must be negative for HCV by polymerase chain reaction (PCR) to be eligible for study participation.
16. Known or suspected history of hemophagocytic lymphohistiocytosis
17. Known or suspected chronic active Epstein-Barr virus (EBV) infection within the last 4 weeks prior to inclusion
18. History of erythema multiforme, Grade ≥3 rash, or blistering following prior treatment with immunomodulatory derivatives
19. History of interstitial lung disease (ILD), drug-induced pneumonitis, and autoimmune pneumonitis
20. Active autoimmune disease requiring treatment
21. History of autoimmune disease, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis; except:
* Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible.
* Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.
* Patients with a history of disease-related immune thrombocytopenic purpura or autoimmune hemolytic anemia may be eligible.
* Patients with a remote history of, or well-controlled autoimmune disease, with a treatment-free interval from immunosuppressive therapy for 12 months may be eligible after review and discussion with the Medical Monitor.
22. Recent major surgery with risk of bleeding within 4 weeks prior to first study treatment administration (C1D1)
23. History of solid organ transplantation
24. Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes an individual's safe participation in and completion of the study
25. Person deprived of his/her liberty by a judicial or administrative decision
26. Person hospitalized without consent
27. Adult person under legal protection
28. Adult person unable to provide informed consent because of intellectual impairment, any serious medical condition, laboratory abnormality or psychiatric illness
29. patient unable to receive at least one of the three regimens of the comparator arm (ICT). As in usual practice, physician has to verify the absence of contraindication to the use of the drugs, hypersensitivity, and to take into account the lymphoma history and previous treatment scheme used
30. Suspicion or clinical evidence of transformed lymphoma at enrollment by investigator assessment (e.g. very high SUV (regarding SUV of other lesions) in at least one lesion that was not biopsied, and discordant with SUV of biopsied lesion, LDH \> 2.5 ULN in a context of rapidly progressive disease, etc. (Please contact the Sponsor to discuss any possible inclusion in borderline cases or any doubt).
31. Uncontrolled symptomatic pleural or serous effusion requiring urgent treatment within 48 hours (patients with controlled disease after adequate pleural/serous drainage and/or effective pleurX™ or similar system are eligible).
32. Uncontrolled symptomatic ureterohydronephrosis resulting in renal failure (patients with adequate management i.e. ureteral catheter or double J stent allowing renal failure control are eligible).
33. MZL with high tumor burden defined as:
* Lymphocytes ≥ 25 G/L, and/or
* Spleen ≥ 17 cm of greatest axis, and/or
* Lymph nodes ≥ 10 cm
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Lymphoma Academic Research Organisation
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Catherine THIEBLEMONT, Pr
Role: PRINCIPAL_INVESTIGATOR
Lymphoma Study Association
Sylvain CARRAS
Role: PRINCIPAL_INVESTIGATOR
Lymphoma Study Association
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
INSTITUT JULES BORDET - Service Hématologie
Anderlecht, , Belgium
UNIVERSITE CATHOLIQUE DE LOUVAIN SAINT-LUC - Service Hématologie
Brussels, , Belgium
UNIVERSITAIR ZIEKENHUIS GENT - Service Hématologie
Ghent, , Belgium
CHU UCL NAMUR - SITE GODINNE - Service Hématologie
Yvoir, , Belgium
CHU d'Amiens
Amiens, , France
CH d'Avignon - Hopital Henri Duffaut
Avignon, , France
CH de la Côte Basque - Hôpital de Bayonne
Bayonne, , France
CHRU Besançon - Hôpital Minjoz
Besançon, , France
Institut Bergonié
Bordeaux, , France
Chu Estaing
Clermont-Ferrand, , France
CHU Henri Mondor
Créteil, , France
CHU de Dijon
Dijon, , France
CHU de Grenoble - Hôpital Albert Michallon
La Tronche, , France
CHRU de LILLE - Claude Huriez
Lille, , France
Institut Paoli Calmette
Marseille, , France
CH Saint-Eloi
Montpellier, , France
CHU de Nancy - Brabois
Nancy, , France
Centre Catherine de Sienne
Nantes, , France
CHU de Nantes - Hôtel Dieu
Nantes, , France
Centre Antoine Lacassagne
Nice, , France
CHU de Nice
Nice, , France
CHR d'Orléans
Orléans, , France
APHP - Hôpital Saint Louis
Paris, , France
CHU Lyon Sud
Pierre-Bénite, , France
CHU de Rennes - Hôpital de Pontchaillou
Rennes, , France
Centre Henri Becquerel
Rouen, , France
Institut de Cancérologie de la Loire Lucien Neuwirth
Saint-Priest-en-Jarez, , France
KLINIKUM ST. MARIEN AMBERG - Hämatologie/Onkologie
Amberg, , Germany
Helios Klinikum Berlin-Buch - Klinik für Hämatologie und Stammzelltransplantation
Berlin, , Germany
UNIVERSITAETSKLINIKUM SCHLESWIG-HOLSTEIN - Med. Klinik II - Hämatologie und Onkologie
Kiel, , Germany
KLINIKUM DER STADT LUDWIGSHAFEN - Hämatologie
Ludwigshafen, , Germany
UNIVERSITATSKLINIKUM REGENSBURG - Klinik für Innere Medizin III
Regensburg, , Germany
ROBERT BOSCH KRANKENHAUS - Hämatologie, Onkologie und Palliativmedizin
Stuttgart, , Germany
MUTTERHAUS DER BORROMAERINNEN - Hämatologie
Trier, , Germany
UNIV KLINIKUM ULM - INNERE MEDIZIN III - Hämatologie
Ulm, , Germany
UNIVERSITY WURZBURG - Hämatologie
Würzburg, , Germany
POLICLINICO SANT'ORSOLA-MALPIGHI - Ematologia
Bologna, , Italy
INSTITUTO ONCOLOGICO VENETO I.R.C.C.S - Ematologia
Castelfranco Veneto, , Italy
AZIENDA OSPEDALIERA S. CROCE E CARLE CUNEO - Ematologia
Cuneo, , Italy
SAPIENZA UNIVERSIT DI ROMA - POLO PONTINO - OSPEDALE S. MARIA GORETTI LATINA - UOC Ematologia
Latina, , Italy
OSPEDALE VITO FAZZI LECCE - Hematologia
Lecce, , Italy
OSPEDALE SAN RAFFAELE - Unità di Ricerca Clinica Linfomi Dipartimento di Onco-ematologia
Milan, , Italy
AZIENDA OSPEDALIERO UNIVERITARIA DI MODENA - Ematologia
Modena, , Italy
POLICLINICO SAN MATTEO - SC Ematologia
Pavia, , Italy
OSPEDALE S. MARIA DELLE CROCI - Dipartimento di Oncologia ed Ematologia
Ravenna, , Italy
AOU CITTA DELLA SALUTE E DELLA SCIENZA DI TORINO - Ematologia
Torino, , Italy
OSPEDALE MAGGIORE ASUGI - UCO Ematologia
Trieste, , Italy
INSTITUTO PORTUGUES DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL - Departamento Hematologia
Lisbon, , Portugal
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Fulvio MASSARO, MD
Role: primary
Sarah BAILLY, MD
Role: primary
Ciel DE VRIENDT
Role: primary
Wivine BERNARD, MD
Role: primary
Caroline DELETTE, MD
Role: primary
Hacene ZERAZHI, MD
Role: primary
Sophie BERNARD, MD
Role: primary
Adrien CHAUCHET, MD
Role: primary
Fontanet BIJOU, Pr
Role: primary
Olivier Tournilhac, MD
Role: primary
Corinne Haioun
Role: primary
Olivier CASASNOVAS, MD
Role: primary
Sylvain CARRAS, MD
Role: primary
Franck MORSHHAUSER, Pr
Role: primary
Aude Collignon, MD
Role: primary
Guillaume CARTRON, MD
Role: primary
Pierre FEUGIER, MD
Role: primary
Nadine Morineau, MD
Role: primary
Béatrice MAHE, MD
Role: primary
Fréderic PEYRADE, Pr
Role: primary
Edmond CHICHE, MD
Role: primary
Marlène OCHMANN, MD
Role: primary
Catherine Thieblemont, Pr
Role: primary
Emmanuel BACHY, MD
Role: primary
Roch HOUOT, MD
Role: primary
Fabrice JARDIN, Pr
Role: primary
Ludovic FOUILLET, MD
Role: primary
Ludwig FISCHER VON WEIKERSTHAL, MD
Role: primary
Bertram GLASS, MD
Role: primary
Christiane POTT, MD
Role: primary
Martin HOFFMANN, MD
Role: primary
Stephanie MAYER, MD
Role: primary
Nicola GIESEN, MD
Role: primary
Rolf MAHLBERG, MD
Role: primary
Christian Buske, Prof.
Role: primary
Johannes DULL, Prof.
Role: primary
Pier Luigi ZINZANI, Prof.
Role: primary
Nilla MASCHIO, MD
Role: primary
Elia BOCCELLATO, MD
Role: primary
Alessandro PULSONI, MD
Role: primary
Nicola Last Name, MD
Role: primary
Andrés JM FERRERI, MD
Role: primary
Giovanna LEONARDI, MD
Role: primary
Luca ARCAINI, MD
Role: primary
Monica TANI, MD
Role: primary
Candida VITALE, MD
Role: primary
Francesco ZAJA, MD
Role: primary
Maria GOMES DA SILVA, MD PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MARSUN
Identifier Type: -
Identifier Source: org_study_id